SciBase Receives Initial Order for Clinical Study with Castle Biosciences

Sep 23, 2025
SciBase has received an initial order for a clinical study from Castle Biosciences, marking the start of their collaboration to develop a test for atopic dermatitis.

SciBase has received an initial order for a clinical study from Castle Biosciences, as announced in a press release. The order, valued at approximately $0.8 million, includes Nevisense Go devices and electrodes. This marks the beginning of their collaboration to develop a test predicting flares in patients with atopic dermatitis.

The collaboration, initially announced in June 2025, involves a license agreement between the two companies. Deliveries for the clinical study are set to begin in the fourth quarter of 2025. Castle Biosciences has also invested in SciBase, becoming its second-largest shareholder. Pia Renaudin, CEO of SciBase, expressed enthusiasm about the collaboration's potential to improve therapies for patients with skin barrier dysfunctions.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.